AstraZeneca In $15 Billion Talks For Drug That Could Upend Lung Cancer Treatment

In a high-stakes maneuver that could reshape the oncology landscape, AstraZeneca Plc (NASDAQ:AZN) is reportedly in talks with Summit Therapeutics Inc. (NASDAQ:SMMT) about a partnership worth up to $15 billion.What Does This Mean?The deal would give AstraZeneca the rights to a lung cancer drug called ivonescimab.Bloomberg reported that the discussions are private, citing sources familiar with the matter. Summit has also been in talks with other large pharmaceutical companies about the same drug.Also Read: Summit Therapeutics’ Closely-Watched Lung Cancer Study Of Ivonescimab Misses Overall Survival EndpointSummit gained traction when, in September 2024, it released data from ...Full story available on Benzinga.comWeiter zum vollständigen Artikel bei Benzinga Weiter zum vollständigen Artikel bei Benzinga